Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Investing in stocks is risky and each stock can have its own set of risks. Below is a list of risks that generally apply to all stocks:

Volatility: The performance of stocks can be volatile, with their value dropping as quickly as it can rise. You should be prepared to lose all the money you invest in stocks.

Liquidity: Some stocks may suffer from low liquidity which could prevent you buying or selling them at the price you want or expect.

Complexity: Specific stocks and ETFs may carry with them specific complex risks that are hard to understand. Do your own research and if something sounds too good to be true, it probably is.

Don’t put all your eggs in one basket: Putting all your money into a single type of investment is risky. Spreading your money across different investments makes you less dependent on any one to do well.

If you want to learn more about specific risks related to equity securities, please visit our dedicated equities disclosure page.